Kintor PharmaceuticalKNTPF 20 Gross Margin % is 30.84% as of Dec. 2025, which is 2348% above its 10-year median of 1.26. GuruFocus rates KNTPF with a GF Score™ of 20/100. The stock has 3 warning signs investors should review. Among 735 Biotechnology companies, Kintor Pharmaceutical ranks worse than 80.27% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Kintor Pharmaceutical had a gross margin of 30.84% for the quarter that ended in Dec. 2025 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Kintor Pharmaceutical Gross Margin % Related Terms
Kintor Pharmaceutical Gross Margin % Historical Data
* Premium members only.
The historical data trend for Kintor Pharmaceutical's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KNTPF vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Kintor Pharmaceutical's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kintor Pharmaceutical Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kintor Pharmaceutical's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Kintor Pharmaceutical's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Kintor Pharmaceutical (KNTPF) has a Gross Margin % of 30.84% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Kintor Pharmaceutical and its competitors. This is 2348% above median its historical median of 1.26. According to the industry distribution chart, Kintor Pharmaceutical ranks #590 out of 735 companies in the Biotechnology industry, placing it in the top 80.3%.
Is Kintor Pharmaceutical's Gross Margin % too high?
Kintor Pharmaceutical's current Gross Margin % of 30.84% is 2348% above median its 10-year median of 1.26. The Biotechnology industry median Gross Margin % is 60.90. Kintor Pharmaceutical's value of 30.84% is 49.4% below this industry median. Based on the distribution chart, Kintor Pharmaceutical ranks #590 out of 735 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kintor Pharmaceutical has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Kintor Pharmaceutical's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kintor Pharmaceutical ranks #590 out of 735 companies for Gross Margin %. This places Kintor Pharmaceutical in the lower half of its industry. The industry median Gross Margin % is 60.90. Kintor Pharmaceutical's value of 30.84% is 49.4% below this benchmark. While the company's 10-year median is 1.26 vs. the industry median of 60.90, Kintor Pharmaceutical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.90, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kintor Pharmaceutical's current Gross Margin % of 30.84% is 49.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Kintor Pharmaceutical and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kintor Pharmaceutical's current Gross Margin % is 30.84%, which is 2348% above median its own 10-year median of 1.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kintor Pharmaceutical stock overvalued right now?
Kintor Pharmaceutical (KNTPF) has a current Gross Margin % of 30.84%. The current Gross Margin % is 30.84%, which is 2348% above median its 10-year median of 1.26 and 49.4% below the Biotechnology industry median of 60.90. Kintor Pharmaceutical's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Kintor Pharmaceutical (KNTPF), the current Gross Margin % is 30.84% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China, focusing on developing therapeutic drugs for unmet medical needs. Its pipelines cover indications of dermatology, such as AGA and acne vulgaris, and indications of tumors, catering to the unmet medical needs of patients and cosmetics consumers globally. The Group's cosmetic product types include anti-hair loss, acne treatment, and skin whitening products. Kintor's pipeline consists of various drug candidates such as KX-826, AR-PROTAC Compound (GT20029), GT1708F (Hedgehog/SMO Inhibitor), GT0486, and ALK-1 Antibody (GT90001). It has only one reportable operating segment, which is engaged in the research and development of medicine products and extends to functional cosmetics and raw materials.
20GF Score
Get the complete analysis for KNTPF
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KNTPF has been successfully added to your 
